Preclinical studies in ccRCC models have shown that efficacy of GLS1 glutaminase inhibitors can be enhanced with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) (15). The gene discussed is GLS; the disease is nonpapillary renal cell carcinoma.